Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Provided By GlobeNewswire
Last update: Mar 6, 2025
Successful End-of-Phase 2 Meeting with FDA and Alignment on Phase 3 Program for Hepatitis C Virus (HCV)
Patient Enrollment in Global Phase 3 HCV Program Expected to Start in April 2025
Read more at globenewswire.com
